heart-failure

The FDA cleared an IND for UHeart, a 10-gene-edited pig heart, opening a single-center phase 1/2/3 trial that will enroll up to two patients with end-stage heart failure before any expansion.

Low-dose digoxin failed its primary endpoint in 1,001 Dutch heart-failure patients, but a JAMA meta-analysis of DECISION, DIGIT-HF and the 1997 DIG trial published the same day finds digitalis cuts the combined risk of cardiovascular death or first worsening event by 15 percent.

Japan's health ministry has conditionally approved two iPS cell-derived drugs, marking the first time regenerative medicines built from induced pluripotent stem cells will reach patients commercially.